HIS separation planned, tariff refund lifts guidance
- Solventum plans to separate its Health Information Systems business to become a pure medical technology company.
- A $100 million tariff refund in Q2 neutralized prior margin pressures in the MedSurg segment.
- Management raised full year EPS guidance to a range of $7.10 to $7.20.
- Underlying financials are noisy right now because of $125 million in advanced orders pulled into Q2.
- The company still faces a major risk from its $3 billion revenue dependency on 3M for materials.
Guidance jumps, but financials are noisy
The story for Solventum changed significantly in Q2 2026. The company announced plans to separate its Health Information Systems business. This move will leave Solventum as a focused medical and dental company. The separation could also generate cash to pay down debt and buy back shares.
The bull case gained momentum thanks to a $100 million tariff refund in the second quarter. This refund wiped out the severe margin pressure the MedSurg segment faced earlier in the year. Management felt confident enough to raise full year EPS guidance to between $7.10 and $7.20. The company is also finally finishing up its distracting software changes from the 3M spin-off, which should improve cash flow by the end of the year.
The bear case centers on messy financial numbers and execution risks. Revenue in Q2 was artificially boosted by $125 million in advanced orders. That pulls sales forward from Q3, making it hard to see the true underlying growth rate. Solventum is also juggling multiple complex projects at once: finishing 3M system cutovers, integrating the Acera acquisition, running a restructuring program, and now carving out a major software segment.
Finn's view is balanced. The stock looks better with the tariff issue resolved and a clear plan to unlock value from the software business. However, the company still has a massive $3 billion supply dependency on 3M that remains unresolved.
Becoming a pure medical device company
Solventum makes money by selling medical supplies, dental products, and healthcare software. MedSurg includes wound care and I.V. site products. Dental Solutions sells items like restorative cements and orthodontic products. The company announced in Q2 2026 that it plans to separate its Health Information Systems software business.
The company is trying to grow through new products and small acquisitions like Acera Surgical. Management limits most deals to under $1 billion. This keeps the focus on smaller targets in familiar markets. Any cash generated from the upcoming software business separation will likely be used to reduce debt and reward shareholders.
The main profit lever is the multi-year Transform for the Future program. This initiative cuts costs and moves spending toward higher growth areas. The company expects these savings to improve operating margins over time.
What Solventum sells
Advanced wound care
This includes single-use negative pressure wound therapy. The Acera Surgical acquisition added regenerative wound care to this group.
I.V. site management
These products help secure and protect I.V. sites in hospitals and clinics.
Infection prevention and surgical solutions
This gives Solventum a large hospital footprint. It is part of the core MedSurg segment.
Dental restorative and prevention
These products include restorative and prevention solutions used by dental offices.
Traditional orthodontics and dental cements
Solventum sells orthodontic products and dental composites. Some of these materials depend heavily on 3M for supply.
Health Information Systems
This software segment helps hospitals code care and manage records. Solventum announced plans to separate this business in Q2 2026.
MedSurg dominates the core business
Shares use Q1 2026 net sales from the Form 10-Q: MedSurg $1,234 million, Dental Solutions $354 million, Health Information Systems $342 million, All Other $76 million. Health Information Systems is now marked for separation.
What could break the story
3M sole-source supply problem
High impact · Medium oddsSolventum depends on 3M as the sole source for materials tied to about $3 billion of fiscal 2025 revenue. A supply disruption or bad pricing reset could hurt sales and margins.
Software separation execution fails
Medium impact · Medium oddsThe company is trying to carve out its Health Information Systems business while finishing 3M system cutovers and a restructuring program. Doing too much at once could cause costly mistakes.
Q3 growth falls apart
Medium impact · High oddsRevenue in Q2 2026 included $125 million in early orders that were pulled forward. When that reverses in Q3, the underlying growth rate might look worse than investors expect.
PFAS liabilities move back into focus
Medium impact · Low oddsSolventum is generally responsible for PFAS related liabilities from its own business after the spin-off. Some 3M indemnification for certain products only extended through the end of 2025.
In one breath
What does Solventum do?
Solventum sells healthcare products and software. It focuses on medical and surgical supplies, dental products, and health software. The company plans to separate the software business soon.
Why did Solventum spin off from 3M?
Solventum became a separate public company so the healthcare business could run with its own strategy and capital plan. The separation created costs and supply ties that are still being resolved.
Is Solventum growing?
Yes, but modestly. Growth numbers are currently distorted by early customer orders, but management recently raised full year expectations.
What is the biggest risk for Solventum stock?
The largest outside risk is the supply dependence on 3M for materials tied to about $3 billion of revenue. The company also faces execution risks as it separates its software business.
